Additionally, chemotherapeutic resistance is another challenge for therapeutic efficacy and patient prognosis, and our analysis showed that CDX2 overexpression in cancer patients with TNM IV stage diseases had a better response to adjuvant chemotherapy with first-line drugs. Here, CDX2 is linked to cancer.